Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 6/20 | 0.35 |
| ▸ | CES2 | O00748 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LSS | P48449 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1230019 | 1.00 | TSHR (0.43) | TSHRLMNATHRBCES1CES2 | |
| SCHEMBL1229816 | 1.00 | TSHR (0.43) | TSHRLMNATHRBCES1CES2 | |
| SCHEMBL29398848 | 0.96 | TSHR (0.46) | TSHRLMNATHRBCES1CES2 | |
| SCHEMBL16432 | 0.96 | TSHR (0.46) | TSHRLMNATHRBCES1CES2 | |
| SCHEMBL1228550 | 0.92 | TSHR (0.43) | TSHRLMNATHRBCES1CES2 | |
| SCHEMBL1230027 | 0.92 | TSHR (0.43) | TSHRLMNATHRBCES1CES2 | |
| SCHEMBL1230281 | 0.92 | TSHR (0.43) | TSHRLMNATHRBCES1CES2 | |
| Hydrochloric Acid SCHEMBL1034009 | 0.92 | — | — | |
| SCHEMBL848566 | 0.92 | TSHR (0.43) | TSHRLMNATHRBCES1CES2 | |
| SCHEMBL10557096 | 0.92 | TSHR (0.43) | TSHRLMNATHRBCES1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692247-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022211-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022211-A1 | CURABLE COMPOSITION | H1-4, H1-0, H1-2 | TSHR 2520/4885LMNA 1462/4885THRB 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.